EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Canonical amplifications and CDKN2A/B loss refine IDH1/2 -mutant astrocytoma prognosis

Hia S Ghosh, Ruchit V Patel iD, Elizabeth B Claus, Luis Nicolas Gonzalez Castro, Patrick Y Wen iD, Keith L Ligon, David M Meredith, Wenya Linda Bi iD

Neuro-Oncology · 15.05.2025 · 27 (4) · 993-1003

DOI: 10.1093/neuonc/noae258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 25.11.2024. Verfasst von Hia S Ghosh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Astrocytoma, Cyclin-Dependent Kinase Inhibitor p16, Brain Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular features have been incorporated alongside histologic criteria to improve glioma diagnostics and prognostication. CDKN2A/B homozygous-loss associates with worse survival in IDH1/2-mutant astrocytomas (IDHmut-astrocytomas), the presence of which denotes a grade 4 tumor independent of histologic features. However, no molecular features distinguish survival amongst histologically defined grade 2 and 3 IDHmut-astrocytomas.

Methods

We assembled a cohort of patients ≥19 years old diagnosed with an IDHmut-astrocytoma between 1989 and 2020 from public datasets and several academic medical centers. Multivariate modeling and unbiased clustering were used to stratify risk.

Results

We identified 998 IDHmut-astrocytoma patients (41.5% female; 85.6% white). Tumor grade, CDKN2A/B loss, and/or ≥1 focal amplification were associated with reduced survival. Grade 2/3 patients with intact CDKN2A/B and no focal amplifications survived the longest (OS 205.7 months). Survival for grade 2/3 cases with either CDKN2A/B hemizygous-loss or focal amplifications (80.4, 88.7 months respectively) did not differ significantly from grade 4 cases with intact CDKN2A/B and no amplifications (91.5 months, P = .93). Grade 4 patients with either hemizygous or homozygous loss of CDKN2A/B had the shortest survival (OS 31.9, 32.5 months respectively), followed by grade 4 cases with intact CDKN2A/B and focal gene amplifications (OS 55.9 months). Integrating CDKN2A/B status and amplifications alongside histopathologic grade refined overall survival prediction. Unbiased clustering revealed 9 distinct molecular profiles, with differential survival. IDHmut-astrocytomas with any CDKN2A/B loss clustered together, regardless of grade, and exhibited the poorest outcomes.

Conclusions

Combining CDKN2A/B hemizygous-loss and focal gene amplifications reveals a group of IDHmut-astrocytoma patients with an intermediate prognosis, refining IDHmut-astrocytoma classification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseAstrocytomaCyclin-Dependent Kinase Inhibitor p16Brain NeoplasmsCyclin-Dependent Kinase Inhibitor p15MutationGene AmplificationBiomarkers, TumorHumansFemaleMalePrognosisMiddle AgedAdultSurvival RateAgedFollow-Up StudiesYoung Adult

Stichwörter der Autor:innen

CDKN2A/B lossIDH1/2-mutant astrocytomafocal amplificationgliomamolecular risk stratification

Substanzen

Isocitrate DehydrogenaseCyclin-Dependent Kinase Inhibitor p16IDH1 protein, humanCyclin-Dependent Kinase Inhibitor p15CDKN2B protein, humanIDH2 protein, humanCDKN2A protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
  • Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Pathology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

ORCID-Profile: Ruchit V Patel, Patrick Y Wen, Wenya Linda Bi

Zitieren

APA

Ghosh, H. S., Patel, R. V., Claus, E. B., Gonzalez Castro, L. N., Wen, P. Y., Ligon, K. L., Meredith, D. M., & Bi, W. L. (2025). Canonical amplifications and CDKN2A/B loss refine IDH1/2 -mutant astrocytoma prognosis. Neuro-Oncology, 27(4), 993-1003. https://doi.org/10.1093/neuonc/noae258

Vancouver

Ghosh HS, Patel RV, Claus EB, Gonzalez Castro LN, Wen PY, Ligon KL, et al. Canonical amplifications and CDKN2A/B loss refine IDH1/2 -mutant astrocytoma prognosis. Neuro-Oncology. 2025;27(4):993-1003. doi:10.1093/neuonc/noae258

BibTeX
@article{Ghosh2025,
  author = {Ghosh, Hia S and Patel, Ruchit V and Claus, Elizabeth B and Gonzalez Castro, Luis Nicolas and Wen, Patrick Y and Ligon, Keith L and Meredith, David M and Bi, Wenya Linda},
  title = {Canonical amplifications and CDKN2A/B loss refine IDH1/2 -mutant astrocytoma prognosis},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {4},
  pages = {993--1003},
  doi = {10.1093/neuonc/noae258}
}
Kostenlos starten →